278 related articles for article (PubMed ID: 29733229)
21. Cutaneous pseudo-T-cell lymphomas. A clinicopathologic study of 20 patients.
Rijlaarsdam JU; Scheffer E; Meijer CJ; Willemze R
Cancer; 1992 Feb; 69(3):717-24. PubMed ID: 1730122
[TBL] [Abstract][Full Text] [Related]
22. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Maj J; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6017-26. PubMed ID: 26504025
[TBL] [Abstract][Full Text] [Related]
23. Expression of CD31 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Grzegrzolka J; Piotrowska A; Gomulkiewicz A; Glatzel-Plucinska N; Olbromski M; Podhorska-Okolow M; Szepietowski JC; Dziegiel P
Anticancer Res; 2016 Sep; 36(9):4575-82. PubMed ID: 27630298
[TBL] [Abstract][Full Text] [Related]
24. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
25. Transformed mycosis fungoides: clinicopathological features and outcome.
Barberio E; Thomas L; Skowron F; Balme B; Dalle S
Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
[TBL] [Abstract][Full Text] [Related]
26. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
27. Mycosis fungoides and Sézary syndrome in Japan. Clinicopathologic study of 107 autopsy cases.
Arai E; Katayama I; Ishihara K
Pathol Res Pract; 1991 May; 187(4):451-7. PubMed ID: 1876527
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
30. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
31. Causes of Death in Cutaneous T-Cell Lymphoma Patients.
Lebas E; Collins P; Somja J; Nikkels AF
Dermatology; 2023; 239(6):860-867. PubMed ID: 37611553
[TBL] [Abstract][Full Text] [Related]
32. Frequency of primary cutaneous lymphoma variants in Austria: retrospective data from a dermatology referral centre between 2006 and 2013.
Eder J; Kern A; Moser J; Kitzwögerer M; Sedivy R; Trautinger F
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1517-23. PubMed ID: 25600184
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical staining for CD45R isoforms in paraffin sections to diagnose mycosis fungoides-type cutaneous T-cell lymphoma.
Ismail SA; Han R; Sanborn SL; Stevens SR; Cooper KD; Wood GS; Gilliam AC
J Am Acad Dermatol; 2007 Apr; 56(4):635-42. PubMed ID: 17367612
[TBL] [Abstract][Full Text] [Related]
34. Involvement of cutavirus in a subset of patients with cutaneous T-cell lymphoma with an unfavorable outcome.
Hashida Y; Nakajima K; Higuchi T; Nakai K; Daibata M
J Clin Virol; 2023 Aug; 165():105523. PubMed ID: 37336173
[TBL] [Abstract][Full Text] [Related]
35. Various skin manifestations of mycosis fungoides: histopathological features and prognosis.
Koga M; Imafuku S; Nakayama J
Fukuoka Igaku Zasshi; 2011 Jul; 102(7):229-36. PubMed ID: 21879593
[TBL] [Abstract][Full Text] [Related]
36. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
Wong HK
G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
[TBL] [Abstract][Full Text] [Related]
37. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
Olsen EA
Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
[TBL] [Abstract][Full Text] [Related]
38. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.
Gjerdrum LM; Woetmann A; Odum N; Burton CM; Rossen K; Skovgaard GL; Ryder LP; Ralfkiaer E
Leukemia; 2007 Dec; 21(12):2512-8. PubMed ID: 17713545
[TBL] [Abstract][Full Text] [Related]
39. Defining early mycosis fungoides: validation of a diagnostic algorithm proposed by the International Society for Cutaneous Lymphomas.
Vandergriff T; Nezafati KA; Susa J; Karai L; Sanguinetti A; Hynan LS; Ambruzs JM; Oliver DH; Pandya AG
J Cutan Pathol; 2015 May; 42(5):318-28. PubMed ID: 25721994
[TBL] [Abstract][Full Text] [Related]
40. Adnexotropic and granulomatous mycosis fungoides following TNF-α inhibitor treatment.
Doughty H; Scripture A; Carter JB; Sriharan A; Yan S; Lansigan F; Momtahen S
J Cutan Pathol; 2023 Jul; 50(7):611-616. PubMed ID: 37127841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
